Michelle L Block

US Patent:

20080038199, Feb 14, 2008

Filed:

May 12, 2005

Appl. No.:

11/596296

Inventors:

Liya Qin - Durham NC, US
Guorong Li - Chapel Hill NC, US
Michelle Block - Holly Springs NC, US
Wei Zhang - Dalian NC, US
Po-See Chen - Taipei City, TW
Giia-Shuen Peng - Taipei-City, TW

Assignee:

The Government of the United States as represented
by The Secretary Department of Health and Human Services - Rockville MD

International Classification:

A61K 31/485
A61K 31/19
A61K 38/00
A61K 38/06
A61K 38/08
A61P 29/00
C07K 2/00
C12N 5/00
C12Q 1/26
G01N 33/50

US Classification:

424009200, 435025000, 435375000, 514017000, 514018000, 514002000, 514282000, 514289000, 514557000, 530300000

Abstract:

The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.

US Patent:

20120142615, Jun 7, 2012

Filed:

Dec 13, 2011

Appl. No.:

13/324876

Inventors:

Liya Qin - Durham NC, US
Guorong Li - Chapel Hill NC, US
Michelle Block - Holly Springs NC, US
Wei Zhang - Dalian, CN
Po-See Chen - Taipei City, TW
Giia-Shuen Peng - Taipei City, TW

Assignee:

Human Service - Bethesda MD

International Classification:

A61K 38/08
A61K 31/19
A61K 38/06
C07K 5/083
A61P 29/00
A61P 25/28
A61P 25/16
A61P 25/00
A61P 9/10
A61P 3/10
A61P 19/02
A61P 37/00
C12N 5/071
C12N 9/99
C12N 5/078
C12Q 1/26
G01N 33/566
A61K 31/485

US Classification:

514 218, 514282, 514557, 514 219, 530331, 435375, 435184, 435 25, 435 721

Abstract:

The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.

US Patent:

20140315785, Oct 23, 2014

Filed:

Jul 3, 2014

Appl. No.:

14/323557

Inventors:

- Rockville MD, US
Liya Qin - Durham NC, US
Guorong Li - Chapel Hill NC, US
Michelle Block - Holly Springs NC, US
Wei Zhang - Dalian, CN
Po-See Chen - Taipei City, TW
Giia-Shuen Peng - Taipei, TW

International Classification:

A61K 38/08
A61K 31/46
A61K 31/19
A61K 38/06

US Classification:

514 14, 435 25, 435375, 514 69, 514 167, 514 177, 514 178, 514 179, 514 218, 514 219, 514282, 514557, 530331

Abstract:

The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.